Common therapies including chemotherapy may increase the risk of tumor metastasis while killing cancer cells. One study has demonstrated that chemotherapy could lead to cancer cell metastasis. For instance, when paclitaxel or carboplatin are used to treat lung tumor-bearing mice, each of the drugs can promote metastasis of the lung cancer cells, while doxorubicin and fluorouracil do not have the same activity. The study further found that paclitaxel can induce high expression of cytokines and angiogenic factors that lead to angiogenesis. The angiogenesis further damaged the integrity of blood vessels and called for bone mallow-derived dendritic cells (BMDCs）to the related organs, subsequently promoting cancer cell proliferation, migration in the microenvironment, and induced epithelial-mesenchymal transitions (EMT), eventually leading to the formation of new metastatic foci. In this case, even if only a small proportion of chemotherapeutic drugs will cause this problem, it will lead to many avoidable deaths. Therefore, the combinational use of anti-cancer drugs and anti-metastatic drugs will significantly increase the survival rate of cancer patients. Currently, Exploring Health LLC is focusing on developing novel anti-metastatic drugs and identifying drugs that possess anti-metastatic effects using  existing drugs.